Compare ASPN & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPN | ENTA |
|---|---|---|
| Founded | 2001 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.5M | 377.5M |
| IPO Year | 2011 | 2012 |
| Metric | ASPN | ENTA |
|---|---|---|
| Price | $5.45 | $11.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $7.75 | ★ $21.83 |
| AVG Volume (30 Days) | ★ 882.8K | 238.7K |
| Earning Date | 11-05-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.93 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $271,103,000.00 | $102,814,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.76 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $2.30 | $10.22 |
| 52 Week High | $8.64 | $17.15 |
| Indicator | ASPN | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 43.60 |
| Support Level | $5.25 | $10.86 |
| Resistance Level | $5.60 | $13.95 |
| Average True Range (ATR) | 0.24 | 0.60 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 48.74 | 29.81 |
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology, supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Thermal Barrier segment and the United States market. Some of its products include Pyrogel XTE, Cryogel Z, Spaceloft Subsea, and others.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.